Matthew Langevin

Matthew Langevin has extensive work experience in the biotechnology and pharmaceutical industries. Matthew has held various roles throughout their career, with a focus on bioanalytical operations, immunoassay development, and research and development.

Matthew's most recent role is as the Chief Operating Officer (COO) at Sword Bio, a position they started in February 2023. In this role, they are responsible for implementing GLP architecture across the company and overseeing all company operations, including CRO service offerings, product development and manufacturing, and creating and maintaining organizational structure.

Prior to their role at Sword Bio, Matthew worked at BioAgilytix Labs, Inc. from 2008 to 2019. Matthew held the position of Director, Bioanalytical Operations and Co-founder from July 2012 to April 2019, and before that, they were the Bioanalytical Project Manager and Co-founder from May 2008 to July 2012.

Before BioAgilytix Labs, Matthew worked at AAIPharma as a Manager, Immunoassay Development from September 2007 to April 2008. In this role, they assisted in the design of a laboratory space and collaborated with various groups to ensure the successful implementation of lab operations.

Matthew also has experience as a research scientist, with roles at Talecris Biotherapeutics from December 2004 to September 2007, Eli Lilly from January 2002 to December 2004, Nobex Corporation from April 2000 to January 2002, and LeukoSite Inc from May 1997 to August 1998. In these positions, they focused on assay development, evaluation of technologies, and providing scientific support for preclinical and clinical studies.

Additionally, Matthew worked as an Associate Scientist at Epic Therapeutics from August 1998 to April 2000, where they specialized in the development and characterization of protein drug delivery systems.

Matthew'searliest work experience was as a Laboratory Technician at Alpha Beta Technologies from January 1995 to May 1997, where they assisted in the development of in vitro potency assays and measured macrophage activity.

Overall, Matthew Langevin has a diverse range of experiences and skills in various aspects of biotechnology and pharmaceutical research, development, and operations.

Matthew Langevin began their education at Bishop Feehan High School, where they studied from 1986 to 1991. Matthew then went on to earn a Bachelor of Science degree in Biotechnology from Worcester Polytechnic Institute, completing their studies from 1991 to 1995. Matthew later pursued further education at Worcester Polytechnic Institute, where they earned a Master of Science degree in Biotechnology from 1995 to 1997.